Skip to main content

Neuromuscular Blockade

37
Pipeline Programs
7
Companies
19
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
10
24
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Merck & Co.
BRIDIONApproved
sugammadex
Merck & Co.
intravenous2015

Competitive Landscape

7 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
22 programs
1
5
11
Deep neuromuscular blockadePhase 4
RocuroniumPhase 4
RocuroniumPhase 41 trial
Rocuronium BromidePhase 4
SugammadexPhase 4
+17 more programs
Active Trials
NCT03039543Completed108Est. Nov 2017
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
21 programs
1
5
10
Deep neuromuscular blockadePhase 41 trial
RocuroniumPhase 41 trial
Rocuronium BromidePhase 41 trial
SugammadexPhase 41 trial
Sugammadex 2 mg/kgPhase 41 trial
+16 more programs
Active Trials
NCT04124757Completed731Est. Jun 2024
NCT02925143Completed6,525Est. Jun 2017
NCT03117387Completed250Est. Jul 2020
+18 more trials
Merck & Co.
Merck & Co.RAHWAY, NJ
5 programs
1
E-learning course in neuromuscular monitoringN/A
Measurements of the level of neuromuscular blockadeN/A
Neuromuscular Blocking AgentN/A
MK-8616PHASE_2
sugammadexPHASE_41 trial
Active Trials
NCT03679611Completed120Est. Oct 2021
Alliance Pharmaceuticals
1 program
1
SugammadexPhase 41 trial
Active Trials
NCT05661409Completed46Est. Aug 2024
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
1
neostigmine/glycopyrrolatePhase 4
Biocorp
BiocorpFrance - Issoire
1 program
1
BX1000Phase 21 trial
Active Trials
NCT05687253Completed80Est. May 2023
Senzime
SenzimeSweden - Uppsala
1 program
neuromuscular blockade monitoringN/A1 trial
Active Trials
NCT03987607Completed50Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsSugammadex
Sharp TherapeuticsRocuronium Bromide
Sharp Therapeuticsneostigmine/glycopyrrolate
Sharp TherapeuticsSugammadex 2 mg/kg
Merck & Co.sugammadex
Sharp TherapeuticsSugammadex 2 mg/kg
Sharp TherapeuticsSugammadex 2 mg/kg ABW
Sharp TherapeuticsSugammadex
MSDRocuronium
Sharp Therapeuticssugammadex
Sharp TherapeuticsDeep neuromuscular blockade
Sharp Therapeuticssufficient dose of rocuronium
Sharp TherapeuticsRocuronium
Sharp TherapeuticsSugammadex
Sharp Therapeuticssugammadex

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 2,968 patients across 19 trials

NCT05661409Alliance PharmaceuticalsSugammadex

Sugammadex as Rescue Therapy

Start: Jul 2023Est. completion: Aug 202446 patients
Phase 4Completed
NCT05562999Sharp TherapeuticsRocuronium Bromide

Impact of Deep Neuromuscular Blockade During Total Hip Replacement Surgery on Postoperative Recovery and Immune Function

Start: Nov 2022Est. completion: Aug 2024100 patients
Phase 4Completed
NCT04606901Sharp Therapeuticsneostigmine/glycopyrrolate

Comparison of Time to Extubation Using Sugammadex or Neostigmine

Start: Apr 2021Est. completion: Jul 202358 patients
Phase 4Completed
NCT03909165Sharp TherapeuticsSugammadex 2 mg/kg

Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

Start: Jul 2019Est. completion: Sep 2023145 patients
Phase 4Completed
NCT03679611Merck & Co.sugammadex

Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

Start: Jan 2019Est. completion: Oct 2021120 patients
Phase 4Completed
NCT03351608Sharp TherapeuticsSugammadex 2 mg/kg

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

Start: Feb 2018Est. completion: Jan 2020288 patients
Phase 4Completed
NCT03346070Sharp TherapeuticsSugammadex 2 mg/kg ABW

Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)

Start: Jan 2018Est. completion: Jan 2019207 patients
Phase 4Completed
NCT03168308Sharp TherapeuticsSugammadex

Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients

Start: Sep 2017Est. completion: Sep 201992 patients
Phase 4Completed
NCT03039543MSDRocuronium

Neuromuscular Blockade During Transurethral Resection of Bladder Cancer

Start: Jun 2017Est. completion: Nov 2017108 patients
Phase 4Completed
NCT02860507Sharp Therapeuticssugammadex

Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

Start: Aug 2016Est. completion: Feb 201850 patients
Phase 4Completed
NCT02794714Sharp TherapeuticsDeep neuromuscular blockade

Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction

Start: Jun 2016Est. completion: Dec 20170
Phase 4Withdrawn
NCT02724111Sharp Therapeuticssufficient dose of rocuronium

Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery

Start: May 2016Est. completion: Feb 201790 patients
Phase 4Completed
NCT02410590Sharp TherapeuticsRocuronium

Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)

Start: Jul 2015Est. completion: Oct 20160
Phase 4Withdrawn
NCT01422304Sharp TherapeuticsSugammadex

Reversal of Neuromuscular Blockade With Sugammadex or Usual Care in Hip Fracture Surgery or Joint (Hip/Knee) Replacement (P07038)

Start: Oct 2011Est. completion: Sep 20121,198 patients
Phase 3Completed
NCT01050543Sharp Therapeuticssugammadex

Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Start: Feb 2010Est. completion: Aug 2010128 patients
Phase 3Completed
NCT00751179Sharp Therapeuticsrocuronium

Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)

Start: Nov 2008Est. completion: Dec 2009161 patients
Phase 3Completed
NCT00656799Sharp Therapeuticssugammadex

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Start: Apr 2008Est. completion: Jul 20096 patients
Phase 3Completed
NCT00535496Sharp Therapeuticssugammadex

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Start: Sep 2007Est. completion: Feb 200891 patients
Phase 3Completed
NCT05687253BiocorpBX1000

Evaluation of Intubation Conditions Following BX1000 or Rocuronium in Subjects Undergoing Surgery

Start: Oct 2022Est. completion: May 202380 patients
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

10 late-stage (Phase 3) programs, potential near-term approvals
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.